|
[1]AASLD/IDSA HCV Guidance Panel.Hepatitis C guidance:AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus[J].Hepatology, 2015, 62 (3) :932-954.
|
|
[2]European Association for the Study of the Liver.EASL recommendations on treatment of hepatitis C 2018[J].J Hepatol, 2018, 69 (2) :461-511.
|
|
[3] Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association.The guideline of prevention and treatment for hepatitis C:A 2015 update[J].J Clin Hepatol, 2015, 31 (12) :1961-1979. (in Chinese) 中华医学会肝病学分会, 中华医学会感染病学分会.丙型肝炎防治指南 (2015年更新版) [J].临床肝胆病杂志, 2015, 31 (12) :1961-1979.
|
|
[4]SMOLDERS EJ, de KANTER CT, de KNEGT RJ, et al.Drugdrug interactions between direct-acting antivirals and psychoactive medications[J].Clin Pharmacokinet, 2016, 55 (12) :1471-1494.
|
|
[5] LIU ZJ, HAN HL.Study on basic and clinical aspects of drug interactions[M].Beijing:People's Medical Publishing House, 2015:1. (in Chinese) 刘治军, 韩红蕾.药物相互作用基础与临床[M].北京:人民卫生出版社, 2015:1.
|
|
[6] Asunaprevir[EB/OL].http://drugs.medlive.cn/drugref/html/19663.shtml. (in Chinese) 阿舒瑞韦软胶囊[EB/OL].http://drugs.medlive.cn/drugref/html/19663.shtml.
|
|
[7]European Medicines Agency.Daklinza summary of product characteristics[EB/OL].http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003768/WC500172848.pdf.
|
|
[8]Food and Drug Administration.Zepatier prescribing information[EB/OL].2018.https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208261s005lbl.pdf.
|
|
[9]European Medicines Agency.Viekirax summary of product characteristics[EB/OL].2015.http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003839/WC500183997.pdf.
|
|
[10]European Medicines Agency.Exviera summary of product characteristics[EB/OL].2015.http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003837/WC500182233.pdf.
|
|
[11]Food and Drug Administration.Vosevi prescribing information[EB/OL].2017.https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209195s002lbl.pdf.
|
|
[12]Food and Drug Administration.Sovaldi prescribing information[EB/OL].2017.https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/204671s012lbl.pdf.
|
|
[13]Food and Drug Administration.Harvoni prescribing information[EB/OL].2017.https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/205834s024lbl.pdf.
|
|
[14]Food and Drug Administration.Epclusa prescribing information[EB/OL].2017.https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208341s009lbl.pdf.
|
|
[15]WANG Q, RAO HY, YU N, et al.Comorbidities and concomitant medication use in adult patients with chronic hepatitis C:A descriptive epidemiological analysis[J].Chin J Hepatol, 2018, 26 (3) :225-232. (in Chinese) 王琴, 饶慧瑛, 于宁, 等.成人慢性丙型肝炎合并疾病及用药现状分析[J].中华肝脏病杂志, 2018, 26 (3) :225-232.
|
|
[16]PLATT L, EASTERBROOK P, GOWER E, et al.Prevalence and burden of HCV co-infection in people living with HIV:A global systematic review and meta-analysis[J].Lancet Infect Dis, 2016, 16 (7) :797-808.
|
|
[17]WANG Q, RAO HY, WEI L.Algorithmic analysis of potential drug-drug interactions using direct-acting antiviral agents and concomitant medications in chronic hepatitis C[J].Chin J Hepatol, 2018, 26 (3) :209-224. (in Chinese) 王琴, 饶慧瑛, 魏来.基于真实世界丙型肝炎合并疾病的潜在药物相互作用及用药推荐[J].中华肝脏病杂志, 2018, 26 (3) :209-224.
|
|
[18]NAPPI A, PERRELLA A, BELLOPEDE P, et al.Safety of new DAAs for chronic HCV infection in a real life experience:Role of a surveillance network based on clinician and hospital pharmacist[J].Infect A-gent Cancer, 2017, 12:12.
|
|
[19]PAPATHEODORIDI M, DALEKOS GN, GOULIS J, et al.Prioritization for interferon-free regimens and potential drug interactions of current direct-acting anti-hepatitis C agents in routine clinical practice[J].Ann Gastroenterol, 2017, 30 (5) :542-549.
|
|
[20]KONDILI LA, GAETA GB, IELUZZI D, et al.Real-life data on potential drug-drug interactions in patients with chronic hepatitis Cviral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort Study[J].PLo S One, 2017, 12 (2) :e0172159.
|
|
[21]GEDDAWY A, IBRAHIM YF, ELBAHIE NM, et al.Direct acting anti-hepatitis C virus drugs:Clinical pharmacology and future direction[J].J Transl Int Med, 2017, 5 (1) :8-17.
|
|
[22]FDA Drug Safety Communication.FDA warns of serious slowing of the heart rate when antiarrhythmic drug amiodarone is used with hepatitis C treatments containing sofosbuvir (Harvoni) or Sovaldi in combination with another direct acting antiviral drug[EB/OL].https://www.fda.gov/Drugs/Drug Safety/ucm439484.htm.
|
|
[23]REGAN CP, MORISSETTE P, REGAN HK, et al.Assessment of the clinical cardiac drug-drug interaction associated with the combination of hepatitis C virus nucleotide inhibitors and amiodarone in guinea pigs and rhesus monkeys[J].Hepatology, 2016, 64 (5) :1430-1441.
|
|
[24]LAGRUTTA A, ZENG H, IMREDY J, et al.Interaction between amiodarone and hepatitis-C virus nucleotide inhibitors in human induced pluripotent stem cell-derived cardiomyocytes and HEK-293 Cav1.2 over-expressing cells[J].Toxicol Appl Pharmacol, 2016, 308:66-76.
|
|
[25]RENET S, CHAUMAIS MC, ANTONINI T, et al.Extreme bradycardia after first doses of sofosbuvir and daclatasvir in patients receiving amiodarone:2 cases including a rechallenge[J].Gastroenterology, 2015, 149 (6) :1378-1380.e1.
|
|
[26]FELD JJ, MORENO C, TRINH R, et al.Sustained virologic response of 100%in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12 weeks[J].JHepatol, 2016, 64 (2) :301-307.
|
|
[27]TALAVERA PONS S, BOYER A, LAMBLIN G, et al.Managing drug-drug interactions with new direct-acting antiviral agents in chronic hepatitis C[J].Br J Clin Pharmacol, 2017, 83 (2) :269-293.
|
|
[28]MENON RM, BADRI PS, WANG T, et al.Drug-drug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevir/ritonavir, ombitasvir, and dasabuvir[J].J Hepatol, 2015, 63 (1) :20-29.
|
DownLoad: